滚动资讯
BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drugEndpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise pushEndpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drugClinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a CrowdBioWorldFirst cruise ship hantavirus genome points to zoonotic spilloverBioWorldBiggest gainers and losers for May 4-8, 2026Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneFierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase dataFierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year planBioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialFDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical NeedsEndpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
资讯库中暂时找不到这篇内容。